Skip to main content
Have a personal or library account? Click to login
Review on analgesic effect of co-administrated ibuprofen and caffeine Cover

Review on analgesic effect of co-administrated ibuprofen and caffeine

Open Access
|May 2014
Read online

References

  1. 1. Addams S.S.: The propionic acids: a personal perspective. J. Clin.Pharmacol., 32 (4), 317-323, 1992.10.1002/j.1552-4604.1992.tb03842.x
  2. 2. Apstein C.S., Vogel W.M.: Coronary arterial vasodilator effect of ibuprofen. J. Pharmacol. Exp. Ther., 220 (1), 167-171, 1982.
  3. 3. Barone J.J., Roberts H.R.: Caffeine consumption. Food Chem.Toxicol., 34, 119-129, 1996.10.1016/0278-6915(95)00093-3
  4. 4. Beaver W.T.: Caffeine revisited. JAMA, 251, 1732-1733, 1984.10.1001/jama.251.13.1732
  5. 5. Bishop D.: Dietary supplements and team-sport performance. Sports Med., 40 (12), 995-1017, 2010.10.2165/11536870-000000000-00000
  6. 6. Chin J.M. et al.: Caffeine content of brewed teas. J. Anal. Toxicol., 32 (8), 702-704, 2008.10.1093/jat/32.8.702
  7. 7. Collins S.L. et al.: Oral ibuprofen and diclofenac in post-operative pain: a quantitative systemic review. J. Pain, 2, 285-291, 1998.10.1016/S1090-3801(98)90027-1
  8. 8. Conger S.A. et al.: Does caffeine added to carbohydrate provide additional ergogenic benefit for endurance? Int. J. Sport Nutr. Exerc.Metab., 21 (1), 71-84, 2011.10.1123/ijsnem.21.1.7121411838
  9. 9. Curhan S.G. et al.: Analgesic use and the risk of hearing loss in men.Am. J. Med., 123 (3), 231-237, 2010.10.1016/j.amjmed.2009.08.006283177020193831
  10. 10. Danckwerts M.P., Watt J.G., Moodley I.: The effect of processing variables on the release of ibuprofen and caffeine from controlledrelease nonswellable core-in-cup compressed tablets. Drug Dev. Ind.Pharm., 22 (7), 681-687, 1996.10.3109/03639049609063224
  11. 11. Derry C.J., Derry S., Moore R.A.: Caffeine as an analgesic adjuvant for acute pain in adults. Cochrane Rev., 3, 2012.10.1002/14651858.CD009281.pub222419343
  12. 12. Diamond S., Balm T.K., Freitag F.G.: Ibuprofen plus caffeine in the treatment of tension-type headache. Clin. Pharmacol. Ther., 68, 312-319, 2000.10.1067/mcp.2000.109353
  13. 13. Dooley J.M. et al.: Caffeine as adjuvant to ibuprofen in treating childhood headaches. Pediatr. Neurol., 37 (1), 42-46, 2007.10.1016/j.pediatrneurol.2007.02.016
  14. 14. Fisone G., Borgkvist A., Usiello A.: Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol. Life Sci., 61 (7-8), 857-872, 2004.10.1007/s00018-003-3269-3
  15. 15. Forbes J.A. et al.: Evacuation of aspirin, caffeine and their combination in postoperative oral surgery pain. Pharmacotherapy, 10, 387-393, 1990.
  16. 16. Fredholm B.B. et al.: Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol.Rev., 51 (1), 83-133, 1999.
  17. 17. Granados-Soto V., Castaneda-Hernandez G.: A review of the pharmacokinetic and pharmacodynamic factors in the potentiation of the antinociceptive effect of nonsteroidal anti-infammatory drugs by caffeine. J. Pharm. Toxicol., 42 (2), 67-72, 1999.10.1016/S1056-8719(00)00044-7
  18. 18. Holtzman S.G., Mante S., Minneman K.P.: Role of adenosine receptors in caffeine tolerance. J. Pharmacol. Exp. Ther., 256 (1), 62-68, 1990.
  19. 19. Kayrak D., Akman U., Hortacsu O.: Micronization of ibuprofen by RESS. J. Supercrit. Fluid., 26, 17-31, 2003.10.1016/S0896-8446(02)00248-6
  20. 20. Khoshayand M.R. et al.: Simultaneous spectrophotometric determination of paracetamol, ibuprofen and caffeine in pharmaceuticals by chemometric methods. Spectrochom. Acta A, 70, 491-499, 2008.10.1016/j.saa.2007.07.03317825606
  21. 21. Koyama R. et al.: Effect of caffeine on ibuprofen-induced gastrin mucosal damage in rats. J. Pharm. Pharmacol., 51, 817-824, 1999.10.1211/002235799177301410467957
  22. 22. Li J., Zhang Y.: Emerging drug targets for pain treatment. Eur. J.Pharmacol., 681 (1-3), 1-5, 2012.10.1016/j.ejphar.2012.01.01722314220
  23. 23. Lopez J.R.M. et al.: Enhancement of antinociception by co-administration of ibuprofen and caffeine in arthritic rats. Eur. J.Pharmacol., 544 (1-3), 31-38, 2006.10.1016/j.ejphar.2006.06.04116872598
  24. 24. Mao J., Gold M.S., Backonja M.: Combination drug therapy for chronic pain: A call for more clinical studies. J. Pain, 12 (2), 157-166, 2011.10.1016/j.jpain.2010.07.006300648820851058
  25. 25. Marczyński Z.: Technologia tabletkowania suchego wyciągu z ziela nawłoci pospolitej (Solidago virgaurea L.) przy użyciu silifikowanej celulozy mikrokrystalicznej (Prosolv) oraz innych wybranych substancji pomocniczych. Polim. Med., 39, 4, 2009.
  26. 26. Martindale: The Complete Drug Reference. [online] London: Pharmaceutical Press http://www.medicinescomplete.com (Accessed04.11.2013).
  27. 27. McQuay H.J. et al.: Ibuprofen compared with ibuprofen plus caffeine after third molar surgery. Pain, 66 (2-3), 247-251, 1996.10.1016/0304-3959(96)03043-6
  28. 28. More P.K., Khomane K.S., Bansal A.K.: Flow and compaction behavior of ultrafine coated ibuprofen. Int. J. Pharm., 441, 527-534, 2013.10.1016/j.ijpharm.2012.10.048
  29. 29. Mumford G.K., Neill D.B., Holtzman S.G.: Caffeine elevates reinforcement threshold for electrical brain stimulation: tolerance and withdrawal changes. Brain Res., 459, 163-167, 1988.10.1016/0006-8993(88)90298-3
  30. 30. Ortega-Alvaro A. et al.: Comparison of the antinociceptive effects of ibuprofen arginate and ibuprofen in rat models of inflammatory and neuropathic pain. Life Sci., 90, 13-20, 2012.10.1016/j.lfs.2011.10.002
  31. 31. Rao P., Knaus E.E.: Evolution of nonsteroidal ant-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond.J. Pharm. Sci., 11 (2), 81-110, 2008.10.18433/J3T886
  32. 32. Ritschel W.A., Kearns G.L. (2009). Handbook of basic pharmacokinetics including clinical applications. In: Appendix pharmacokinetics parameters of important drugs. Washington D.C.: APhA; p. 440.10.21019/9781582121260
  33. 33. Sawynok J., Yaksh T.L.: Caffeine as an analgesic adjuvant: a review of pharmacology and mechanisms of action. Pharmacol. Rev., 45, 43-85, 1993.
  34. 34. Sawynok J.: Adenosine receptor activation and nociception. Eur. J.Pharmacol., 317, 1-11, 1998.10.1016/S0014-2999(97)01605-1
  35. 35. Sillanpaa M., Piekkala P.: Prevalence of migraine and other headaches in early puberty. Scand. J. Prim. Health Care, 2, 27-32, 1984.10.3109/02813438409017698
  36. 36. Tarnopolsky M.A.: Caffeine and creatine use in sport. Ann. Nutr.Metab., 57 (2), 1-8, 2010.10.1159/000322696
  37. 37. Tavares C., Sakata R.K.: Caffeine in the treatment of pain. Rev. Bras.Anestesiol., 62 (3), 387-401, 2012.10.1016/S0034-7094(12)70139-3
  38. 38. Wee B., Hillier R.: Pain control. Med., 39 (11), 639-644, 2011.10.1016/j.mpmed.2011.08.012
  39. 39. World Health Organization. (1996). Cancer pain relief. Geneva, WHO.
DOI: https://doi.org/10.2478/cipms-2014-0003 | Journal eISSN: 2300-6676 | Journal ISSN: 2084-980X
Language: English
Page range: 10 - 13
Submitted on: Dec 6, 2013
Accepted on: Feb 14, 2014
Published online: May 30, 2014
Published in print: Jun 1, 2014
Published by: Sciendo
In partnership with: Paradigm Publishing Services

© 2014 Andrzej Polski, Regina Kasperek, Karolina Sobotka-Polska, Ewa Poleszak, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.